Megan Brooks

Megan Brooks is a long‑tenured medical writer who covers new clinical evidence and emerging therapies across neurology, oncology, cardiology, infectious disease, and other specialties for Medscape. Her work is distinguished by a tight focus on how specific drugs, supplements, technologies, and environmental exposures alter risk and outcomes, and by clear, study‑driven reporting aimed at a professional clinical readership.

Neurology and brain health

A consistent through‑line in Brooks’s coverage is brain health, especially the ways everyday exposures shape neurodegeneration and cerebrovascular risk. She reports on environmental factors such as chronic glyphosate exposure, detailing research that links regulated‑level herbicide exposure with increased neuroinflammation, Alzheimer’s‑like protein changes, and persistent brain tissue metabolites in animal models. She has covered long‑term biomarker studies that map the timing of changes as patients move from normal cognition toward dementia, underscoring how subtle shifts accumulate over decades.

Medication and substance risks are another recurring theme. Brooks has written on the elevated dementia risk seen in older adults who use benzodiazepines, highlighting roughly 50% higher risk compared with non‑users. She has explored the debated connection between cannabis use and stroke, examining whether observed associations reflect a causal link or confounding factors in young stroke patients. Her reporting frequently returns to Alzheimer’s disease progression and dementia prevention, tying together pharmaceuticals, supplements, and lifestyle factors as modifiable levers for clinicians and patients.

Beyond risk, she covers interventions that directly target the brain. Brooks has reported on “brain retraining” approaches that deliver lasting relief for chronic back pain, emphasizing how cognitive and neuroplasticity‑based therapies can outperform traditional pain management strategies. She has also written about how proximity to nature influences brain regions involved in stress and attention, translating imaging and behavioral data into practical insights on environmental enrichment and mental health. Across these pieces, she stays close to trial design, imaging findings, and quantitative outcomes, and frames them in terms of what they mean for neurologists, psychiatrists, and pain specialists.

Devices, digital tools, and innovative therapies

Brooks frequently covers novel technologies and non‑pharmacologic interventions that could change how clinicians monitor and treat disease. In cardiology, she has reported on a smartphone‑based system that uses voice analysis to detect congestion in heart failure, explaining how remote monitoring could supplement clinical visits and guide timely therapy adjustments. She has highlighted robotic wearables that help children with spinal muscular atrophy stand, focusing on functional gains and the potential to reshape pediatric rehabilitation.

Her neurology and psychiatry coverage includes multiple device‑driven and AI‑enabled therapies. Brooks has written about AI‑powered wearables designed to calm essential tremor, detailing how these devices modulate symptoms and where they fit alongside established treatments. She has covered transnasal cooling as a promising intervention for migraine, summarizing early‑stage evidence and patient‑reported outcomes. She reports on AI tools developed to predict psychosis before it occurs, outlining their performance characteristics and the implications for early intervention in high‑risk populations.

Across these stories, Brooks emphasizes the evidence behind technological claims, often presenting how tools performed in trials, what endpoints they achieved, and which patient groups benefited. Her format is typically concise news grounded in data rather than product promotion, making her a key explainer of emerging digital health and device‑based therapies for clinicians evaluating new options.

Cancer, cardiology, and systemic disease

Brooks’s beat extends across systemic diseases, with oncology and cardiovascular medicine featuring prominently. She has reported on whether fasting around chemotherapy improves outcomes for patients with ovarian cancer, describing study protocols, survival and toxicity metrics, and the practical considerations of integrating fasting regimens into standard care. In cardio‑oncology, she has covered findings that radiation therapy for lung cancer may increase the risk of atrial fibrillation, framing the results in terms of treatment planning and long‑term cardiac surveillance.

Her work often tracks how exposures outside the traditional risk profile affect systemic disease. Brooks has written on burn pit exposure in veterans and its association with increased neurologic risk, joining occupational and environmental medicine with neurology and primary care. She has reported on a self‑administered treatment showing promise in myasthenia gravis, explaining both efficacy and feasibility for patients managing a chronic neuromuscular condition. She has also covered guidance urging caution before surgery in refractory constipation, emphasizing when invasive procedures should be deferred in favor of medical and behavioral management.

Cardiovascular topics recur in her coverage, including heart failure monitoring technologies and arrhythmia risk associated with cancer therapies, and she consistently presents these findings through the lens of risk‑benefit trade‑offs and long‑term outcomes. The unifying element is close attention to how new data might change clinical decision‑making, rather than broad lifestyle advice.

Infectious disease and clinical evidence for practice

Brooks also writes on infectious diseases and public health questions where emerging evidence has immediate practice implications. She has co‑authored coverage of mpox (monkeypox) transmission, noting data that more than half of viral transmissions may occur before symptom onset, which carries direct consequences for isolation guidance and contact tracing. These pieces foreground transmission dynamics, population data, and the timing of infection, making complex epidemiologic findings usable for clinicians.

Across specialties, her work is consistently evidence‑forward. Brooks has been a medical writer and editor for more than 30 years, focusing exclusively on science writing for a professional audience. Her news articles tend to center on peer‑reviewed studies, large cohort analyses, randomized trials, and specialty‑society recommendations, and she distills these into short, direct stories that highlight key numbers, effect sizes, and caveats. The distinctive feature of her coverage is this rigorous, study‑based approach applied across diverse conditions, with particular depth in brain health, technology‑driven interventions, and the systemic effects of drugs and environmental exposures.